Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier

Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However, DPP4 mutations in humans or the long-term outcomes of high glucagon-like peptide-1...

Full description

Bibliographic Details
Main Authors: Dandan Zhao, Shaoqian Zhao, Xiao Wang, Mingbo Su, Wen Liu, Qinyun Ma, Jie Hong, Weiqiong Gu, Jingya Li, Ruixin Liu, Guang Ning, Jiqiu Wang, Yifei Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Endocrinology
Subjects:
dipeptidyl peptidase IV
glucagon-like peptide-1
β-cell function
type 2 diabetes
incretin effect
Online Access:http://journal.frontiersin.org/article/10.3389/fendo.2018.00062/full

Internet

http://journal.frontiersin.org/article/10.3389/fendo.2018.00062/full

Similar Items